Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04523181 · ClinicalTrials.gov registry record · Phase 2
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
A Phase 2 study of COVID-19, sponsored by Golden Biotechnology Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 15
- Study locations
NCT04523181: Completed Phase 2 study of COVID-19, sponsored by Golden Biotechnology Corporation.
NCT04523181 is a Phase 2 study of COVID-19 that has completed, run by Golden Biotechnology Corporation. The registered enrollment target is 124 participants, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04523181, a Phase 2 study of COVID-19, has completed, sponsored by Golden Biotechnology Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 15
- Study locations
Study Summary
To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
Primary Outcome
Number of Patients Who are Alive and Free of Respiratory Failure (e.g., no need for invasive mechanical ventilation, non invasive ventilation, high flow oxygen, or ECMO) on Day 14.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Antroquinonol
Study Locations (15)
Other
- Unidad de Investigacion, Hospital Nacional IV Alberto Sabogal Sologuren-Essalud, Red Assitencial Sabogal - Callao
- Hospital de Chancay - Chancay
- Asociación Civil Selva Amazónica - Iquitos
- Hospital III Daniel Alcides Carrion - EsSalud - Tacna
Buenos Aires F.D.
- Centro Gallego - Buenos Aires
- Clinica de los Virreyes - Buenos Aires
Indiana
- Franciscan Health Michigan City - Michigan City
Kansas
- Ascension.Via Christi Research - Wichita
Maryland
- Adventist Healthcare Shady Grove Medical Center - Rockville
New Jersey
- South Jersey Infectious Disease - Somers Point
North Carolina
- Duke University Southeastern Health - Lumberton
Ciudad de Cordoba
- Sanatorio Privado Mayo SA - Córdoba
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2021-12-23 |
| Phase | Phase 2 |
What the finished NCT04523181 record still lists
NCT04523181 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 38,465-participant average among 298 other COVID-19 trials with a reported enrollment target (100% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04523181 lists 15 locations in 11 states (Other, Buenos Aires F.D., Indiana).
Frequently Asked Questions
What is clinical trial NCT04523181 about?
NCT04523181 is a clinical study titled "Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients". To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.
What is the current status of trial NCT04523181?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2020-10-15. Estimated completion is 2021-12-23.
What conditions does trial NCT04523181 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04523181?
The interventions under investigation include: Placebo (OTHER), Antroquinonol (DRUG).
Who is sponsoring clinical trial NCT04523181?
This trial is sponsored by Golden Biotechnology Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04523181 being conducted?
This trial has 15 study locations across Indiana, Kansas, Maryland, New Jersey, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04523181's enrollment target sits among peer trials
124 188th of 298 higher than 111 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI